Z-1561-2020 Class II Terminated
FDA device recall Z-1561-2020 was initiated by Dexcom Inc on Feb 3, 2020 and is designated Class II. Reason for recall: The company identified potential interference from hydroxyurea. Patient use of the anti-neoplastic drug may falsely elevate glucose readings on the Continuous Glucose Monitoring Systems. The recall status is terminated (terminated Jan 20, 2022). Affected quantity: 85529 Systems.
Recall details
- Product Type
- Devices
- Report Date
- Apr 1, 2020
- Initiation Date
- Feb 3, 2020
- Termination Date
- Jan 20, 2022
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 85529 Systems
Product description
Reason for recall
Distribution pattern
World-wide Distribution
Code information
Source
- Dataset
- openFDA device recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for Z-1561-2020
- openFDA file date
- Nov 19, 2026
- Loaded by RegDataLab
- Nov 20, 2026
Need the full FDA record for Dexcom Inc? Ask Claude or ChatGPT with the RegDataLab connector and get every site's inspections, Form 483s, warning letters, recalls and import alerts, each with a link to the FDA source. The API key is free: no card.